NOTE: Prior winners:
2022: Anthony Filiano, PhD, Neurosurgery
2022: Pranam Chatterjee, PhD, Biomedical Engineering
2021: Andrew Landstrom, MD, PhD, Pediatrics
2020: Roarke Horstmeyer, PhD, Biomedical Engineering
2019: Neil K. Surana, MD, PhD, Pediatrics
2018 Eileen T. Chambers, MD, Pediatrics
2017 Nick Heaton, PhD, Molecular Genetics and Microbiology
2016 Debra Silver, PhD, Molecular Genetics and Microbiology
2015 Diego Bohorquez, PhD, Medicine - Gastroenterology
2014 Lawrence David, PhD, Molecular Genetics and Microbiology
2012 Mary Hutson, PhD, Pediatrics-Neonatology
2011 Mary Louise Markert, MD, Ph.D., Departments of Pediatrics and Immunology
2010 Patrick C. Seed, MD, PhD, Pediatrics.
2009 Charles Gersbach, PhD, Biomedical Engineering
2008 Cynthia Toth, MD, Ophthalmology
2006 Guoping Feng, PhD, Neurobiology
2006 Jingdong Tian, PhD, Biomedical Engineering
Owing to the sponsor’s restriction on the number of applications that may be submitted from Duke, anyone wishing to pursue nomination should submit the following materials as one PDF.
Text: 1-inch margins, single-column text, single line spacing and black 12-point Times Roman font. Do not indent paragraphs; separate paragraphs from each other by 6-point spacing. Use bold font only for section headings.
Lay Summary – provide in a single paragraph a description of the proposed research (450 words or less) suitable for a nontechnical audience:
- Statement of Problem – description and magnitude of the problem in the United States; emphasize what makes the problem translationally important (e.g., prevalence, incidence, morbidity, and mortality rates) or strategic (focused development of innovation). Ignore economic considerations.
- Compelling Interest – identify what constitutes an unmet need and how addressing it successfully will benefit or improve health outcomes for children in the United States.
- Innovation – identify the novel idea(s), discovery, or creative insight, including relevant model test systems, important experiments or a novel technologic approach that will be used to construct or test hypotheses, which may offer a unique translational benefit, inspire a distinctive shift in perspective, or provide a strategic advantage that may accelerate clinical discovery and translational research.
- Justification for Funding – describe what will happen if the proposed research is successful (e.g., diagnosis, therapeutic intervention, prevention, clinical trials, etc.) and how successful outcomes will be deployed either translationally or strategically to benefit children.
Early-Stage, Innovative and Cutting-Edge Research – avoiding the use of any obscure technical terms, acronyms, abbreviations, or nuanced jargon that are unlikely to be understood by a lay reader, explain explicitly in three separate paragraphs how the research is:
- Early-Stage – the first sentence must begin “My research is early-stage because…” Describe the early-stage nature of the proposed research, but not from the perspective that as a Nominee it represents a new area of interest. Justify how the research may be pioneering and is not simply an incremental advancement or extension of existing research by the Nominee or others; discuss the origin and timing of any discovery or first recognition of the innovation (e.g., the date of first disclosure of intellectual property) or the date of acquisition of any preliminary data. Note: Preliminary data is not a prerequisite for funding consideration but may provide an indication of the early-stage nature of the research.
- Innovative – the first sentence must begin “My research is innovative because…” Characterize how your proposed research is fundamentally new and original or represents a different approach that overcomes limitations compared to known competing approaches; and how if you are successful the outcome will generate a dynamic tactical advantage or create paradigm-shifting strategic value. Describe how your innovation(s) when clinically translated will provide a benefit that addresses an unmet need or will lead to a heretofore unrecognized benefit.
- Cutting-Edge – the first sentence must begin “My research is cutting-edge because…” Describe how the proposed research will utilize state-of-the-art technology and/or a ground-breaking approach that will promote success of the proposed research (e.g., how the questions being posed reflect a particular importance and how they will have the greatest possibility of advancement using the specified technology).
A CV or biosketch – Please include current and pending sources of funding. Please include award amount.
Please submit internal materials through My Research Proposal. (Code: ILN) https://www.grantinterface.com/sl/0fKoEG
Instructions for creating an account (if needed) and submitting your materials: https://ctsi.duke.edu/about-myresearchproposal